Form 4: Chimerix VP Jakeman Reports Share Disposal Following Merger with Jazz Pharmaceuticals

David Jakeman, VP of Finance and Accounting at Chimerix, reports the disposal of shares and cancellation of stock options following the merger with Jazz Pharmaceuticals.

Summary

• David Jakeman, VP of Finance and Accounting at Chimerix, filed a Form 4 to report changes in beneficial ownership of Chimerix stock.
• The filing is related to the merger between Chimerix and Jazz Pharmaceuticals, which became effective on April 21, 2025.
• As a result of the merger, Jakeman disposed of 156,209 shares of common stock at a price of $8.55 per share.
• Outstanding stock options were also affected, with 'in the money' options being cancelled and converted into the right to receive a cash payment, while other options were cancelled with no consideration.
• Restricted stock units (RSUs) were cancelled and converted into the right to receive a cash payment based on the offer price of $8.55 per share.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports the execution of a previously announced merger. While some individuals may benefit from cash payments for shares and options, others may view the loss of independent ownership negatively.

Positives

• The merger provided a cash payment of $8.55 per share for common stock.
• In-the-money stock options were converted to cash, providing some value to option holders.

Negatives

• Out-of-the-money stock options were cancelled with no compensation.
• Shareholders no longer own shares in Chimerix as a result of the merger.

Risks

• The document does not explicitly mention any ongoing risks, but the merger means Chimerix will operate as a subsidiary of Jazz Pharmaceuticals, which could impact future strategic decisions.

Future Outlook

The document does not contain specific forward-looking statements from the reporting person, but the merger indicates a change in the company's future direction under Jazz Pharmaceuticals' ownership.

Industry Context

The acquisition of Chimerix by Jazz Pharmaceuticals reflects ongoing consolidation in the pharmaceutical industry, where larger companies acquire smaller firms with promising drug candidates or technologies.

Comparison to Industry Standards

• Mergers and acquisitions are common in the pharmaceutical industry, with deal valuations varying based on the target company's pipeline, revenue, and growth potential.
• Comparing the $8.55 per share offer to other recent acquisitions in the sector would provide a benchmark for assessing the fairness of the deal.

Stakeholder Impact

• Shareholders received $8.55 per share in cash.
• Employees with in-the-money stock options received cash payments.
• Employees with out-of-the-money stock options received no compensation for their options.
• The company will now operate as a subsidiary of Jazz Pharmaceuticals, which may impact future employment and operational decisions.

Key Dates

Keywords

Chimerix, Jazz Pharmaceuticals, Merger, Form 4, Jakeman, Stock Options, Shares, Beneficial Ownership